Biodesix (BDSX) Projected to Post Earnings on Thursday

Biodesix (NASDAQ:BDSX) is expected to issue its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect the company to announce earnings of ($1.05) per share and revenue of $26.25 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Biodesix Price Performance

Shares of BDSX opened at $12.57 on Thursday. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 41.11. Biodesix has a twelve month low of $3.44 and a twelve month high of $20.40. The firm has a market capitalization of $100.06 million, a PE ratio of -2.26 and a beta of 0.67. The stock’s 50 day moving average is $8.72 and its two-hundred day moving average is $8.11.

Wall Street Analyst Weigh In

Several equities research analysts have commented on BDSX shares. Canaccord Genuity Group restated a “buy” rating and set a $20.00 target price on shares of Biodesix in a research report on Tuesday. Wall Street Zen upgraded shares of Biodesix from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Biodesix in a research report on Monday, December 22nd. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Biodesix has an average rating of “Moderate Buy” and an average target price of $32.50.

Insider Activity at Biodesix

In related news, CEO Scott Hutton sold 3,559 shares of the company’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $10.08, for a total value of $35,874.72. Following the sale, the chief executive officer owned 45,413 shares of the company’s stock, valued at approximately $457,763.04. This represents a 7.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jack W. Schuler bought 82,465 shares of the stock in a transaction on Thursday, January 22nd. The shares were bought at an average price of $10.96 per share, for a total transaction of $903,816.40. Following the acquisition, the director owned 1,463,210 shares in the company, valued at $16,036,781.60. The trade was a 5.97% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have purchased 182,465 shares of company stock valued at $2,084,616 and have sold 7,672 shares valued at $73,576. Insiders own 30.10% of the company’s stock.

Institutional Investors Weigh In On Biodesix

Hedge funds and other institutional investors have recently modified their holdings of the company. Cetera Investment Advisers purchased a new position in shares of Biodesix during the fourth quarter valued at approximately $68,000. Trexquant Investment LP acquired a new position in Biodesix in the 4th quarter valued at $187,000. State Street Corp lifted its stake in shares of Biodesix by 15.6% during the 4th quarter. State Street Corp now owns 17,802 shares of the company’s stock worth $121,000 after purchasing an additional 2,400 shares during the period. DRW Securities LLC acquired a new stake in shares of Biodesix during the fourth quarter worth $105,000. Finally, Geode Capital Management LLC grew its position in shares of Biodesix by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 42,453 shares of the company’s stock valued at $289,000 after purchasing an additional 2,235 shares during the period. 20.96% of the stock is currently owned by hedge funds and other institutional investors.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.